Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Read more about Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma Read more about A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC Read more about PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis Read more about A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Read more about Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer Read more about A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure Read more about Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
A Study to Assess Growth in Children With Idiopathic Short Stature Read more about A Study to Assess Growth in Children With Idiopathic Short Stature
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma Read more about Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) Read more about VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)